Predictors of Treatment Failure with Sofosbuvir/Daclatasvir Regimen for 12 Weeks in Patients with Chronic HCV in Egypt

Background: Hepatitis C virus HCV infection is one of the main causes chronic liver disease worldwide, Egypt has highest national-level prevalence in world, Sofosbuvir/ Daclatasvir (SOF/DAC) regimen widely used to treat Egypt.
 Aims: identify predictors treatment failure with Sofosbuvir/Daclatasvir for 12 weeks Egyptian patients.
 Methodology: A retrospective cohort, we investigated 2300 patients received SOF/DAC Results: Patients who completed and follow up visits were 2079 patients,4 stopped due side effects, 35 incompliance 182 missed their after treatment, out 2043 (98.3%) responded SVR12 just 36 (1.7%) had failure, presence Hypertension (p=0.001), Diabetes Miletus ALT level >51 (p=0.013) , AST >60 (p=0.002), AFP > 6 (p=0.000) abnormal echo-pattern all found have an impact on rates, some other factors be insignificant as age, sex, BMI, special habits, function tests, haemoglobin, total leucocytic count serum creatinine, by multivariate analysis was strongest predictor cut off value >6 sensitivity 66.67% specificity 77.31%.
 Conclusion: This study shows that ALT, AST, AFP, Abnormal Liver Echo-pattern Presence or affect SVR but a cutoff >6.